Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMPK6YT)

• Drug Name: 3,4-diphenyl-1H-pyrrole-2,5-dione Drug Info
• Synonyms: 2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; 3,4-diphenyl-1H-pyrrole-2,5-dione; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 2752461
  CAS Number: CAS 31295-36-0
  TTD Drug ID: DMPK6YT

Molecule-Related Drug Atlas

Drug(s) Targeting Protein kinase C epsilon (PRKCE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Meprobamate	DMHM93Y	Anxiety		Approved	[2]
Bryostatin-1	DM1JOXY	Alzheimer disease	8A20	Phase 2	[3]
RO-320432	DMFZ1YW	N. A.	N. A.	Terminated	[4]
LY-317644	DMM20PI	N. A.	N. A.	Terminated	[5]
CDE-6960	DMA0DKI	Inflammation	1A00-CA43.1	Terminated	[6]
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[7]
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	DMDO175	Discovery agent	N.A.	Investigative	[1]
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	DMGC7RY	Discovery agent	N.A.	Investigative	[1]
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione	DM3EV9N	Discovery agent	N.A.	Investigative	[1]
LY-326449	DMN53M4	Discovery agent	N.A.	Investigative	[8]

Drug(s) Targeting G1/S-specific cyclin-E1 (CCNE1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PD-0183812	DMWYP86	Retinoblastoma	2D02.2	Terminated	[9]
4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol	DMSKJ1X	Discovery agent	N.A.	Investigative	[10]
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	DMDO175	Discovery agent	N.A.	Investigative	[1]
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	DMGC7RY	Discovery agent	N.A.	Investigative	[1]
BMS-536924	DMXJB4N	Discovery agent	N.A.	Investigative	[11]
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione	DM3EV9N	Discovery agent	N.A.	Investigative	[1]
aloisine A	DM5U1LN	Discovery agent	N.A.	Investigative	[12]
3-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol	DMJZK40	Discovery agent	N.A.	Investigative	[10]
(2'Z,3'E)-5-Chloro-5'-chloro-indirubin-3'-oxime	DMGXRSZ	Discovery agent	N.A.	Investigative	[13]
(2'Z,3'E)-5-Chloro-5'-methyl-indirubin-3'-oxime	DMZ0V6G	Discovery agent	N.A.	Investigative	[13]

Drug(s) Targeting G1/S-specific cyclin-D1 (CCND1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ABT-263	DMNE56X	Myelofibrosis	2A20.2	Phase 3	[14]
Briciclib	DMK7BND	Solid tumour/cancer	2A00-2F9Z	Phase 1	[15]
4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol	DMSKJ1X	Discovery agent	N.A.	Investigative	[10]
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	DMDO175	Discovery agent	N.A.	Investigative	[1]
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	DMGC7RY	Discovery agent	N.A.	Investigative	[1]
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione	DM3EV9N	Discovery agent	N.A.	Investigative	[1]
7-hydroxycoumarin	DMTMNO7	Discovery agent	N.A.	Investigative	[16]

Drug(s) Targeting Protein kinase C alpha (PRKCA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sodium phenylbutyrate	DMXLBCQ	Spinal muscular atrophy	8B61	Approved	[17]
Sotrastaurin acetate	DME53YS	Renal transplantation	NE84	Phase 2	[18]
PMID28460551-Compound-3	DMA1FRM	N. A.	N. A.	Patented	[19]
ISIS 3521	DMZFS69	N. A.	N. A.	Discontinued in Phase 2	[20]
BALANOL	DMDLN9E	N. A.	N. A.	Terminated	[21]
RO-320432	DMFZ1YW	N. A.	N. A.	Terminated	[4]
LY-317644	DMM20PI	N. A.	N. A.	Terminated	[5]
Acteoside	DM0YHKB	Nephritis	GB40	Terminated	[22]
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[7]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	DMN9YOB	Discovery agent	N.A.	Investigative	[23]

Drug(s) Targeting Protein kinase C gamma (PRKCG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Midostaurin	DMI6E0R	Acute myeloid leukaemia	2A60	Approved	[24]
BALANOL	DMDLN9E	N. A.	N. A.	Terminated	[21]
RO-320432	DMFZ1YW	N. A.	N. A.	Terminated	[4]
LY-317644	DMM20PI	N. A.	N. A.	Terminated	[5]
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[7]
Bisindolylmaleimide-I	DMOQJZC	Discovery agent	N.A.	Investigative	[25]
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	DMDO175	Discovery agent	N.A.	Investigative	[1]
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	DMGC7RY	Discovery agent	N.A.	Investigative	[1]
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione	DM3EV9N	Discovery agent	N.A.	Investigative	[1]
LY-326449	DMN53M4	Discovery agent	N.A.	Investigative	[8]

Drug(s) Targeting Cyclin-dependent kinase 1 (CDK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
R-roscovitine	DMSH108	Non-small-cell lung cancer	2C25.Y	Phase 2	[26]
Ro 31-7453	DM83QCL	Solid tumour/cancer	2A00-2F9Z	Phase 2	[24]
P276-00	DM9DJL2	Mantle cell lymphoma	2A85.5	Phase 2	[26]
P-276	DMMJUHD	Breast cancer	2C60-2C65	Phase 2	[27]
RGB-286638	DMEGOQP	Haematological malignancy	2B33.Y	Phase 1	[28]
AG-024322	DMY4WVK	Solid tumour/cancer	2A00-2F9Z	Phase 1	[26]
PHA-793887	DM2Y4FG	Solid tumour/cancer	2A00-2F9Z	Phase 1	[29]
Oxazolyl methylthiothiazole derivative 1	DMZM6FW	N. A.	N. A.	Patented	[30]
PMID25991433-Compound-A1	DM89LF0	N. A.	N. A.	Patented	[31]
KENPAULLONE	DMAGVXW	Discovery agent	N.A.	Patented	[32]

Drug(s) Targeting Epidermal growth factor receptor (EGFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[33]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[34]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[35]
Erlotinib	DMCMBHA	Adrenal gland neoplasm		Approved	[36]
Vandetanib	DMRICNP	Solid tumour/cancer	2A00-2F9Z	Approved	[24]
Dacomitinib	DMOH8VY	Non-small-cell lung cancer	2C25.Y	Approved	[37]
BIBW 2992	DMTKD7Q	Non-small-cell lung cancer	2C25.Y	Approved	[38]
SKI-758	DMQ8E9R	Ischemia	8B10-8B11	Approved	[39]
Epidermal growth factor	DMVONE6	Vulnerary	ND56.Z	Approved	[37]
Merimepodib	DM0HS92	Breast cancer	2C60-2C65	Approved	[40]

Drug(s) Targeting Cyclin-dependent kinase 2 (CDK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
R-roscovitine	DMSH108	Non-small-cell lung cancer	2C25.Y	Phase 2	[26]
Ro 31-7453	DM83QCL	Solid tumour/cancer	2A00-2F9Z	Phase 2	[24]
PHA848125	DMS2Q9G	Thymic cancer	2C27	Phase 2	[41]
TG02	DMZFIGQ	Anaplastic astrocytoma	2A00.0	Phase 1/2	[42]
NUV-422	DMQJQNT	Malignant glioma	2A00.0	Phase 1/2	[43]
RGB-286638	DMEGOQP	Haematological malignancy	2B33.Y	Phase 1	[28]
FN-1501	DM7BMD6	Solid tumour/cancer	2A00-2F9Z	Phase 1	[44]
AG-024322	DMY4WVK	Solid tumour/cancer	2A00-2F9Z	Phase 1	[26]
PHA-793887	DM2Y4FG	Solid tumour/cancer	2A00-2F9Z	Phase 1	[29]
SNS-032	DMEITAS	Solid tumour/cancer	2A00-2F9Z	Phase 1	[45]

Drug(s) Targeting Vascular endothelial growth factor receptor 2 (KDR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[46]
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[47]
Regorafenib	DMHSY1I	Gastrointestinal stromal tumour	2B5B	Approved	[48]
Sunitinib	DMCBJSR	Acute undifferentiated leukemia		Approved	[49]
Axitinib	DMGVH6N	Renal cell carcinoma	2C90	Approved	[50]
Vandetanib	DMRICNP	Solid tumour/cancer	2A00-2F9Z	Approved	[24]
Pazopanib HCl	DM6U9CQ	Renal cell carcinoma	2C90	Approved	[51]
Fruquintinib	DMHOSCQ	Colorectal cancer	2B91.Z	Approved	[52]
Cabozantinib	DMIYDT4	Medullary thyroid gland carcinoma		Approved	[53]
Tivozanib	DMUKC5L	Renal cell carcinoma	2C90	Approved	[54]

Drug(s) Targeting Cyclin-dependent kinase 4 (CDK4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Apremilast	DMTWS9E	Psoriasis vulgaris	EA90	Approved	[55]
LY2835219	DM93VBZ	Breast cancer	2C60-2C65	Approved	[56]
Palbociclib	DMD7L94	Breast cancer	2C60-2C65	Approved	[57]
Ribociclib Succinate	DM9CIUW	Breast cancer	2C60-2C65	Approved	[58]
Trilaciclib	DMP5A4T	Small-cell lung cancer	2C25.Y	Approved	[59]
LEE011	DMMX75K	Breast cancer	2C60-2C65	Phase 3	[60]
Ro 31-7453	DM83QCL	Solid tumour/cancer	2A00-2F9Z	Phase 2	[24]
P276-00	DM9DJL2	Mantle cell lymphoma	2A85.5	Phase 2	[26]
P-276	DMMJUHD	Breast cancer	2C60-2C65	Phase 2	[61]
G1T38	DMQO2IT	Breast cancer	2C60-2C65	Phase 2	[14]

Drug(s) Targeting Cyclin-dependent kinase 6 (CDK6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Apremilast	DMTWS9E	Psoriasis vulgaris	EA90	Approved	[55]
LY2835219	DM93VBZ	Breast cancer	2C60-2C65	Approved	[56]
Palbociclib	DMD7L94	Breast cancer	2C60-2C65	Approved	[57]
Ribociclib Succinate	DM9CIUW	Breast cancer	2C60-2C65	Approved	[58]
Trilaciclib	DMP5A4T	Small-cell lung cancer	2C25.Y	Approved	[59]
LEE011	DMMX75K	Breast cancer	2C60-2C65	Phase 3	[60]
G1T38	DMQO2IT	Breast cancer	2C60-2C65	Phase 2	[14]
GLR2007	DM7DWLY	Glioblastoma of brain	2A00.00	Phase 1/2	[62]
FCN-437	DMQ8VUW	Breast cancer	2C60-2C65	Phase 1/2	[63]
NUV-422	DMQJQNT	Malignant glioma	2A00.0	Phase 1/2	[43]

Drug(s) Targeting Angiopoietin 1 receptor (TEK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AKB-9778	DMKNRYH	Diabetic macular edema	9B71.02	Phase 2	[64]
DCC-2036	DMJKFNU	Chronic myeloid leukaemia	2A20	Phase 1/2	[14]
Altiratinib	DMUJCBT	Solid tumour/cancer	2A00-2F9Z	Phase 1	[65]
CEP-11981	DMYDTJ6	Solid tumour/cancer	2A00-2F9Z	Phase 1	[66]
ARRY-614	DMXD93K	Arthritis	FA20	Discontinued in Phase 1	[67]
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	DMDO175	Discovery agent	N.A.	Investigative	[1]
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	DMGC7RY	Discovery agent	N.A.	Investigative	[1]
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione	DM3EV9N	Discovery agent	N.A.	Investigative	[1]
PMID21561767C8h	DMABZH6	Discovery agent	N.A.	Investigative	[68]
(4-Phenoxy-phenyl)-quinazolin-4-yl-amine	DMFO8DR	Discovery agent	N.A.	Investigative	[69]

Drug(s) Targeting ERBB2 messenger RNA (HER2 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
HKI-272	DM6QOVN	Breast cancer	2C60-2C65	Phase 3	[70]
BMS-690514	DMX302C	Chronic pain	MG30	Phase 2	[71]
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	DMDO175	Discovery agent	N.A.	Investigative	[1]
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	DMGC7RY	Discovery agent	N.A.	Investigative	[1]
BMS-536924	DMXJB4N	Discovery agent	N.A.	Investigative	[11]
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione	DM3EV9N	Discovery agent	N.A.	Investigative	[1]
PMID24915291C38	DMBXT9J	Discovery agent	N.A.	Investigative	[72]
Geldanamycin-estradiol hybrid	DMUSJ96	Discovery agent	N.A.	Investigative	[73]
CL-387785	DMLKFZC	Discovery agent	N.A.	Investigative	[74]
HDS-029	DMLRUVA	Discovery agent	N.A.	Investigative	[74]

Drug(s) Targeting G2/mitotic-specific cyclin B1 (CCNB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
KENPAULLONE	DMAGVXW	Discovery agent	N.A.	Patented	[32]
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[75]
Bisindolylmaleimide-I	DMOQJZC	Discovery agent	N.A.	Investigative	[75]
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	DMDO175	Discovery agent	N.A.	Investigative	[1]
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	DMGC7RY	Discovery agent	N.A.	Investigative	[1]
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione	DM3EV9N	Discovery agent	N.A.	Investigative	[1]
AZAKENPAULLONE	DM61H07	Discovery agent	N.A.	Investigative	[76]
Thieno analogue of kenpaullone	DMIOTHG	Discovery agent	N.A.	Investigative	[76]
3,4-bis(indol-3-yl)maleimide derivative	DMEQ1HC	Discovery agent	N.A.	Investigative	[75]
4-(Quinolin-4-yl)-N-p-tolylpyrimidin-2-amine	DMDW3SX	Discovery agent	N.A.	Investigative	[77]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Angiopoietin 1 receptor (TEK)	TT9VGXW	TIE2_HUMAN	Inhibitor	[1]
Cyclin-dependent kinase 1 (CDK1)	TTH6V3D	CDK1_HUMAN	Inhibitor	[1]
Cyclin-dependent kinase 2 (CDK2)	TT7HF4W	CDK2_HUMAN	Inhibitor	[1]
Cyclin-dependent kinase 4 (CDK4)	TT0PG8F	CDK4_HUMAN	Inhibitor	[1]
Cyclin-dependent kinase 6 (CDK6)	TTO0FDJ	CDK6_HUMAN	Inhibitor	[1]
Epidermal growth factor receptor (EGFR)	TTGKNB4	EGFR_HUMAN	Inhibitor	[1]
ERBB2 messenger RNA (HER2 mRNA)	TTR5TV4	ERBB2_HUMAN	Inhibitor	[1]
G1/S-specific cyclin-D1 (CCND1)	TTFCJ7S	CCND1_HUMAN	Inhibitor	[1]
G1/S-specific cyclin-E1 (CCNE1)	TTCEJ4F	CCNE1_HUMAN	Inhibitor	[1]
G2/mitotic-specific cyclin B1 (CCNB1)	TT9P6OW	CCNB1_HUMAN	Inhibitor	[1]
Protein kinase C alpha (PRKCA)	TTFJ8Q1	KPCA_HUMAN	Inhibitor	[1]
Protein kinase C epsilon (PRKCE)	TTBZ7OD	KPCE_HUMAN	Inhibitor	[1]
Protein kinase C gamma (PRKCG)	TTRFOXJ	KPCG_HUMAN	Inhibitor	[1]
Vascular endothelial growth factor receptor 2 (KDR)	TTUTJGQ	VGFR2_HUMAN	Inhibitor	[1]

References

• [1] Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
• [2] Protein kinase C, an elusive therapeutic target . Nat Rev Drug Discov. 2012 December; 11(12): 937-957.
• [3] Protein kinase epsilon dampens the secretory response of model intestinal epithelia during ischemia. Surgery. 2001 Aug;130(2):310-8.
• [4] Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994).
• [5] Synthesis of bisindolylmaleimide macrocycles, Bioorg. Med. Chem. Lett. 5(18):2093-2096 (1995).
• [6] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025002)
• [7] Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides. J Med Chem. 1992 Jan;35(1):177-84.
• [8] (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H... J Med Chem. 1996 Jul 5;39(14):2664-71.
• [9] Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. J Med Chem. 2000 Nov 30;43(24):4606-16.
• [10] 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
• [11] Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.
• [12] Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J Med Chem. 2003 Jan 16;46(2):222-36.
• [13] 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706.
• [14] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [15] Clinical pipeline report, company report or official report of Onconova.
• [16] Decrease of cyclin D1 in the human lung adenocarcinoma cell line A-427 by 7-hydroxycoumarin. Lung Cancer. 2001 Nov;34(2):185-94.
• [17] Polo-like kinase inhibitor Ro5203280 has potent antitumor activity in nasopharyngeal carcinoma.Mol Cancer Ther. 2013 Aug;12(8):1393-401.
• [18] Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
• [19] Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jul;27(7):753-761.
• [20] Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer.Lung Cancer.2006 May;52(2):173-80.
• [21] Evaluation of differential hypoxic cytotoxicity and electrochemical studies of nitro 5-deazaflavins, Bioorg. Med. Chem. Lett. 5(18):2155-2160 (1995).
• [22] Phenylethanoid glycosides from Digitalis purpurea and Penstemon linarioides with PKCalpha-inhibitory activity. J Nat Prod. 1998 Nov;61(11):1410-2.
• [23] Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
• [24] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [25] Protein kinase C epsilon regulates gamma-aminobutyrate type A receptor sensitivity to ethanol and benzodiazepines through phosphorylation of gamma2... J Biol Chem. 2007 Nov 9;282(45):33052-63.
• [26] Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
• [27] P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther. 2007 Mar;6(3):926-34.
• [28] Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75.
• [29] A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected h... Cell Cycle. 2011 Mar 15;10(6):963-70.
• [30] Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
• [31] c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
• [32] Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening followed by in vitro bioassay. Eur J Med Chem. 2010 Sep;45(9):4316-30.
• [33] Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
• [34] Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
• [35] Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72.
• [36] Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48.
• [37] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
• [38] Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
• [39] Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
• [40] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [41] Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor. J Med Chem. 2009 Aug 27;52(16):5152-63.
• [42] Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. Drug Metab Lett. 2012 Mar;6(1):33-42.
• [43] ClinicalTrials.gov (NCT04541225) Phase 1/2 Dose Escalation, Safety, Pharmacokinetics, and Efficacy Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors. U.S.National Institutes of Health.
• [44] Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518.
• [45] Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113(19):4637-45.
• [46] Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
• [47] Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93.
• [48] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [49] 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
• [50] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [51] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [52] Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635-45.
• [53] Clinical pipeline report, company report or official report of Exelixis (2011).
• [54] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
• [55] Agreement signed with Prostagenics to develop prostate cancer treatment. Innovate Oncology, Inc. 2005.
• [56] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [57] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2017
• [58] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [59] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
• [60] Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013 Nov 15;19(22):6173-82.
• [61] Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154.
• [62] Clinical pipeline report, company report or official report of Gan & Lee Pharmaceuticals.
• [63] Clinical pipeline report, company report or official report of Fochon Pharmaceuticals.
• [64] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [65] Clinical pipeline report, company report or official report of Deciphera Pharmaceuticals.
• [66] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1842).
• [67] Cmpany report (Arraybiopharma)
• [68] Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3743-8.
• [69] Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I. Bioorg Med Chem Lett. 2000 Oct 2;10(19):2167-70.
• [70] Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19936-41.
• [71] Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci. 2010 Aug;99(8):3579-93.
• [72] Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28.
• [73] Synthesis and evaluation of geldanamycin-estradiol hybrids. Bioorg Med Chem Lett. 1999 May 3;9(9):1233-8.
• [74] Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB... J Med Chem. 2006 Feb 23;49(4):1475-85.
• [75] Design of new inhibitors for cdc2 kinase based on a multiple pseudosubstrate structure. Bioorg Med Chem Lett. 1998 May 5;8(9):1019-22.
• [76] 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6.
• [77] Synthesis and cytotoxic activity of 2-methylimidazo[1,2-a]pyridine- and quinoline-substituted 2-aminopyrimidine derivatives. Eur J Med Chem. 2010 Jan;45(1):379-86.